Stress-buffering effect of social support on immunity and infectious risk during chemotherapy for breast cancer.

OBJECTIVE: This study investigated the stress-buffering effect of social support on immune function and infectious risk in women with breast cancer, during and after chemotherapy. METHOD: Data were collected from 50 women with breast cancer before and after their chemotherapy, as well as three months later. Stress was measured by daily hassles related to cancer and social support by marital status (MS) and perceived support from friends (Ps-fr). Blood was collected to measure innate immune markers (i.e., T cells, NK cells and neutrophils). Infections were evaluated using a semi-structured interview. Moderation, mediation and moderated mediation models were computed to test the hypotheses. RESULTS: Higher stress at baseline was found to significantly predict a higher occurrence of infections during chemotherapy, but not three months later. The relationship between stress and infections was not significantly explained by any of the immune markers. The interaction between stress and social support was tested using MS alone and combined with Ps-fr. A protective effect of social support on the deleterious effect of stress on infectious risk was found. Single patients reporting lower Ps-fr showed the strongest association between stress and infections, while the weakest association was found in patients in a committed relationship with a higher level of Ps-fr. CONCLUSIONS: Women experiencing more stress before the beginning of chemotherapy would appear to be at a higher risk of developing infections during their treatment. Results of this study also suggest that this effect could be buffered by the presence of a romantic partner and by higher Ps-fr.

Efficacy of a stepped care approach to deliver cognitive-behavioral therapy for insomnia in cancer patients: a noninferiority randomized controlled trial.

STUDY OBJECTIVES: Cognitive-behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for cancer-related insomnia, but its accessibility is very limited in routine care. A stepped care approach has been recommended as a cost-effective way to make CBT-I more widely accessible. However, no controlled study has yet been published about the efficacy of this approach. The goal of this noninferiority randomized controlled trial (RCT) was to compare the short and long-term efficacy of a stepped care CBT-I (StepCBT-I) to a standard face-to-face CBT-I (StanCBT-I). METHODS: A total of 177 cancer patients were randomized to: (1) StanCBT-I (6 face-to-face CBT-I sessions; n = 59) or (2) StepCBT-I (n = 118). In the StepCBT-I group, patients with less severe insomnia first received a web-based CBT-I (n = 65), while those with more severe insomnia received 6 face-to-face CBT-I sessions (n = 53). In both cases, patients could receive up to three booster sessions of CBT-I if they still had insomnia symptoms following this first step. RESULTS: Results indicated that the Step-CBT-I group showed an Insomnia Severity Index score reduction and a sleep efficiency (on a sleep diary) increase that was not significantly inferior to that of StanCBT-I at all post-treatment time points. Analyses of secondary outcomes indicated significant time effects (ps < .001) and no significant group-by-time interactions (ps from .07 to .91) on other sleep diary parameters, sleep medication use, depression, anxiety, fatigue, and quality of life scores. CONCLUSION(S): The efficacy of stepped care CBT-I is not inferior to that of a standard face-to-face intervention and is a valuable approach to making this treatment more widely accessible to cancer patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01864720 (https://clinicaltrials.gov/ct2/show/NCT01864720?term=Savard&draw=2&rank=6; Stepped Care Model for the Wider Dissemination of Cognitive-Behavioural Therapy for Insomnia Among Cancer Patients).

Insomnia, immunity, and infections in cancer patients: Results from a longitudinal study.

BACKGROUND: Insomnia is very common in cancer patients receiving chemotherapy. Poor sleep is associated with immune alterations but the actual impact on health resulting from such immune changes has rarely been studied. The aim of this study was to evaluate, in women treated with chemotherapy for breast or gynecological cancer, the relationships between insomnia, immunity, and the occurrence of infections. METHOD: Fifty-two patients were assessed before chemotherapy (Time [T]1), on 4 occasions during the first 2 cycles of chemotherapy (i.e., on immunosuppression and recovery weeks; T2-T5), at posttreatment (T6), and at 3-month (T7) and 6-month (T8) follow-ups. A clinical interview was administered to assess insomnia (Insomnia Interview Schedule) and the occurrence of infections. Patients were categorized into 1 of these 3 subgroups on the basis of the insomnia interview at T1: good sleepers (GS), insomnia symptoms (SX), and insomnia syndrome (SYN). Finally, blood samples were collected at each time point (T1-T8) to measure several immune parameters (e.g., neutrophils, lymphocytes). RESULTS: Mixed-model analyses of covariance revealed that SYN patients at T1 had significantly lower counts of some blood cells after chemotherapy (T6) as compared to GS (i.e., total white blood cells and neutrophils) and as compared to GS and SX patients (i.e., total lymphocytes, CD3+ and CD4+ cells). At T8, SYN patients at T1 showed significantly lower lymphocytes, CD3+ and CD4+ counts as compared to SX patients. Finally, SYN patients at T1 were at a significantly higher risk of reporting infectious episodes at T5 as compared to SX patients. CONCLUSIONS: Although replication is warranted, these results suggest that prechemotherapy insomnia may potentiate the vulnerability to show immune alterations and develop infections due to chemotherapy during the cancer care trajectory. Overall, they further emphasize the need to provide effective treatments for sleep difficulties in patients undergoing chemotherapy. (PsycInfo Database Record (c) 2020 APA, all rights reserved).

Feasibility of a Cognitive-Behavioral and Environmental Intervention for Sleep-Wake Difficulties in Community-Dwelling Cancer Patients Receiving Palliative Care.

BACKGROUND: High rates of sleep-wake difficulties have been found in patients with cancer receiving palliative care. Pharmacotherapy is the most frequently used treatment option to manage these difficulties despite numerous adverse effects and the absence of empirical evidence of its efficacy and innocuity in palliative care. OBJECTIVE: This pilot study aimed to assess the feasibility and acceptability of a cognitive-behavioral and environmental intervention (CBT-E) to improve insomnia and hypersomnolence in patients with a poor functioning level and to collect preliminary data on its effects. METHODS: Six patients with cancer receiving palliative care (Eastern Cooperative Oncology Group score 2-3), who had insomnia and/or hypersomnolence, received 1 CBT-E individual session at home. They applied the strategies for 3 weeks. Patients completed the Insomnia Severity Index, the Epworth Sleepiness Scale, a daily sleep diary, and a 24-hour actigraphic recording (7 days) at pretreatment and posttreatment, in addition to a semistructured interview (posttreatment). RESULTS: Participants found strategies easy to apply most of the time, and none was rated as impossible to use because of their health condition. However, their adherence and satisfaction toward CBT-E were highly variable. Results on the effects of CBT-E were heterogeneous, but improvements were observed in patients with a persistent insomnia disorder. CONCLUSIONS: The CBT-E protocol tested among this highly selected sample was fairly well received and suggested positive outcomes in some patients, particularly those with an insomnia complaint alone. IMPLICATIONS: Efforts should be pursued to adapt CBT-E and develop other nonpharmacological interventions, in order to provide an alternative to pharmacotherapy for sleep-wake difficulties in this population.

Sleep-wake difficulties in community-dwelling cancer patients receiving palliative care: subjective and objective assessment.

OBJECTIVE: Prevalence rates of sleep difficulties in advanced cancer patients have varied widely across studies (12 to 96%), and none of these employed a diagnostic interview to distinguish different types of sleep-wake disorders. Moreover, very limited information is available on subjective and objective sleep parameters in this population. Our study was conducted in palliative cancer patients and aimed to assess rates of sleep-wake disorders and subsyndromal symptoms and to document subjective and objective sleep-wake parameters across various types of sleep-wake difficulties. METHOD: The sample was composed of 51 community-dwelling cancer patients receiving palliative care and having an Eastern Cooperative Oncology Group score of 2 or 3. Relevant sections of the Duke Interview for Sleep Disorders were administered over the phone. An actigraphic recording and a daily sleep diary were completed for 7 consecutive days. RESULTS: Overall, 68.6% of the sample had at least one type of sleep-wake difficulty (disorder or symptoms): 31.4% had insomnia and 29.4% had hypersomnolence as their main sleep-wake problem. Participants with insomnia as their main sleep difficulty had greater disruptions of subjective sleep parameters, while objectively-assessed sleep was more disrupted in patients with hypersomnolence comorbid with another sleep-wake difficulty.Significance of the Results:The high rates of sleep-wake difficulties found in this study indicate a need to screen more systematically for sleep-wake disorders, including insomnia and hypersomnolence, in both palliative care research and clinical practice, and to develop effective nonpharmacological interventions specifically adapted to this population.

To be or not to be positive: Development of a tool to assess the relationship of negative, positive, and realistic thinking with psychological distress in breast cancer.

There is a widespread belief that positive thinking is a key strategy to cope with cancer. While dispositional optimism is associated with lower psychological distress, the literature supporting the efficacy of cognitive-behavioral therapy indirectly suggests that realistic thinking is also effective. This article describes the development of the Thoughts and Anticipations about Cancer questionnaire designed to directly compare the effect of realistic thinking versus positive thinking on adjustment to cancer. Preliminary data on its relationships with psychological distress gathered in 10 breast cancer patients are promising. The validity of the Thoughts and Anticipations about Cancer questionnaire will need to be confirmed in larger studies.

Treatment of depressive symptoms in patients with breast cancer: A randomized controlled trial comparing cognitive therapy and bright light therapy.

OBJECTIVE: This randomized controlled trial (RCT), conducted in patients with breast cancer, aimed to compare the effects of cognitive therapy (CT), bright light therapy (BLT), and a waiting-list control condition (WLC) on depressive symptoms. METHOD: Sixty-two women were randomly assigned to an 8-week CT (n = 25), BLT (n = 26), or WLC (n = 11). Participants completed the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D), the Beck Depression Inventory-II (BDI-II), and the Hamilton Depression Rating Scale (HDRS) at pre- and posttreatment (and postwaiting for WLC), as well as 3 and 6 months later. RESULTS: At posttreatment, CT patients had a significantly greater reduction of depressive symptoms than WLC on the HADS-D and the BDI-II. BLT patients had a greater reduction of depressive symptoms than WLC on the HADS-D only. After WLC participants were reassigned to CT or BLT, a superiority of CT over BLT was found on the BDI-II at posttreatment. Patients of both active conditions showed a good sustainment of treatment gains at follow-ups. CONCLUSIONS: Although replication with larger samples is needed, these results confirm the efficacy of CT for depression in the context of breast cancer and suggest that BLT could be of some utility when CT is not available or desired. (PsycINFO Database Record

Moderators of Treatment Effects of a Video-Based Cognitive-Behavioral Therapy for Insomnia Comorbid With Cancer.

PURPOSE: To assess the moderating role of demographic and clinical variables on the efficacy of a video-based cognitive behavioral therapy for insomnia (VCBT-I) among breast cancer patients. PATIENTS AND METHODS: As part of a randomized controlled trial, 80 women received VCBT-I. RESULTS: Patients with a more advanced breast cancer were less likely to show reductions on the Insomnia Severity Index (ISI) and increased sleep efficiency at posttreatment. Patients using an antidepressant medication showed a larger reduction of ISI scores and a higher rate of insomnia remission. Remission of insomnia was also significantly more likely in individuals with a higher annual income. When using a multivariate binary classification tree analysis, the best and unique predictor of insomnia remission was having a less severe baseline ISI score. CONCLUSION: Although efficacious in general, VCBT-I does not appear to be an optimal format for everybody.

Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population.

INTRODUCTION: This study aims to empirically validate the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC), a measure of health-related quality of life for prostate cancer patients. METHODS: Two hundred fifty-one participants completed a battery of self-report scales, including the French-Canadian version of the EPIC, after having received radiation therapy or radical prostatectomy for prostate cancer. RESULTS: The internal consistency for the urinary incontinence, bowel, and sexual domains of the EPIC-26 was high (Cronbach's alpha coefficients from 0.80-0.92), while coefficients for the urinary irritation/obstruction (0.59) and hormonal (0.67) domains were lower. Item-total correlations (rs=0.15-0.85), and temporal stability (rs=0.72-0.93) generally supported the reliability of the instrument. The five-factor structure of the EPIC-26 was confirmed for the most part. The construct validity of the instrument was also supported by high correlations obtained between each domain and measures assessing similar constructs (rs=-0.56-0.83). The EPIC also showed an excellent sensitivity to change with significant differences obtained on EPIC scores (all p<0.05) between pre- and post-prostate cancer treatment. CONCLUSIONS: The psychometric qualities of the French-Canadian version of the EPIC are well-supported, thus providing a valid tool to assess health-related quality of life in prostate cancer patients.

Predictors of Smoking Cessation and Relapse in Cancer Patients and Effect on Psychological Variables: an 18-Month Observational Study.

BACKGROUND: Although cancer patients are generally strongly advised to quit smoking in order to improve treatment efficacy and survival, up to 68 % of patients who were smokers at the time of cancer diagnosis continue smoking. Psychological factors such as depression and anxiety are likely to be associated with smoking behavior following a cancer diagnosis, but the empirical evidence is scarce. PURPOSE: This observational study aimed at estimating smoking cessation rates and assessing the effect of smoking cessation on psychological symptoms, as well as the predictive role of the same psychological variables on smoking cessation and smoking relapse following cancer surgery. METHODS: As part of a larger prospective, epidemiological study, smokers (n = 175) with a first diagnosis of nonmetastatic cancer completed the Hospital Anxiety and Depression Scale, the Insomnia Severity Index, and the Fear of Cancer Recurrence Inventory. Quitters (n = 55) and pair-matched nonquitters (n = 55) were compared on each symptom at pre-quitting, post-quitting, and at a 4-month follow-up. Predictors of smoking cessation and smoking relapse, including psychological variables, were also investigated. RESULTS: Fifty-five patients (31.4 %) stopped smoking at least on one occasion during the study. Of the 55 quitters, 27 (49.1 %) experienced a relapse. At pre-quitting, quitters had significantly higher levels of anxiety (p = .03) and fear of cancer recurrence (p = .01) than nonquitters, symptoms that significantly diminished at post-quitting and 4 months later in this subgroup of patients. Having breast cancer significantly predicted smoking cessation (relative risk [RR] = 3.08), while depressive symptoms were a significant predictor of smoking relapse (RR = 1.07). CONCLUSIONS: This study highlights the importance of psychological symptoms in predicting tobacco cessation and relapse among individuals with cancer. Our findings suggest that breast cancer patients are more inclined to stop smoking than patients with other cancers, but future studies should attempt to delineate the effect on smoking cessation of gender and other demographics that characterize this subgroup. This study also suggests that a particular attention should be paid to the early management of depressive symptoms in order to prevent smoking relapse.

Temporal relationships between sleep and physical activity among breast cancer patients with insomnia.

OBJECTIVE: The present study prospectively investigated the day-to-day bidirectional relationships between objective measures of sleep parameters and physical activity among breast cancer patients with insomnia symptoms. METHOD: A subgroup of participants (N = 66) enrolled in a randomized controlled trial for insomnia comorbid with cancer wore an actigraphic recorder for seven 24-hr periods before the intervention. Multilevel models examined whether sleep parameters (sleep onset latency, wake after sleep onset [WASO], total wake time [TWT], sleep efficiency [SE], and total sleep time [TST]) on a given night predicted the levels of physical activity (daily activity counts and minutes of moderate to vigorous physical activity [MVPA]) the following day and vice versa. RESULTS: Adjusted models revealed that a lower WASO (ß= -.12, SE = .07, p < .05), TWT (ß = -.14, SE = .05, p < .05), and TST (ß = -.14, SE = .06, p < .05) were significantly associated with a greater daily activity count fluctuation the next day. Conversely, greater total daily count fluctuations were significantly associated with a higher WASO (ß = .18, SE = .08, p < .05), TWT (ß = .12, SE = .04, p < .05), and TST (ß = .22, SE = .08, p < .05) the following night. CONCLUSIONS: These findings support a reciprocal and complex relationship between sleep parameters and physical activity. While they do not confirm a possible beneficial effect of physical activity on objective sleep parameters, they suggest that successful insomnia treatment could increase daily physical activity in patients with cancer. (PsycINFO Database Record

Capacity of the Edmonton Symptom Assessment System and the Canadian Problem Checklist to screen clinical insomnia in cancer patients.

PURPOSE: Insomnia is highly prevalent in cancer patients. Efficacious treatments exist for this condition but, for these interventions to be offered, an effective screening needs to be carried out beforehand. The pan-Canadian practice guidelines on sleep disturbances provide recommendations on how to use the Edmonton Symptom Assessment System (ESAS) and the Canadian Problem Checklist (CPC) to screen for sleep difficulties in cancer. However, empirical evidence to support these recommendations is lacking. The goal of this study was to assess the capacity of the ESAS (drowsiness and "other" items) and the CPC (sleep item) to screen for clinical insomnia in cancer patients. METHODS: As part of routine care, 615 patients with various cancer types completed the ESAS, the CPC, and the Insomnia Severity Index, used as the standard for establishing the presence of clinical insomnia. RESULTS: None of the criteria provided an effective screening when used alone. No patient used the ESAS-other item to report sleep difficulties. The sensitivity and specificity rates of the CPC-sleep item alone were 60.4 and 89.6 %, respectively. A score ≥2 on the ESAS-drowsiness item had a sensitivity of 61.5 % and a specificity of 75.4 %. When used in combination, the best option was scoring positively on the CPC-sleep item OR a score ≥2 on the ESAS-drowsiness item (sensitivity 84.2 %; specificity 69.7 %). CONCLUSIONS: When used alone, the CPC-sleep and the ESAS-drowsiness items yielded insufficient sensitivity rates for a first screening, but when used in combination, they provided a good balance between sensitivity and specificity.

Long-Term Effects of Two Formats of Cognitive Behavioral Therapy for Insomnia Comorbid with Breast Cancer.

STUDY OBJECTIVES: The goal of this randomized controlled trial, conducted in breast cancer patients, was to assess the long-term efficacy of a video-based cognitive behavioral therapy for insomnia (VCBT-I), as compared to a professionally administered intervention (PCBT-I) and to a no-treatment group (CTL). An earlier report revealed that, at posttreatment, VCBT-I patients showed significantly greater sleep improvements than CTL, but that PCBT-I produced superior effects than VCBT-I on some sleep and secondary outcomes. In this report, long-term effects are compared. METHODS: Two hundred forty-two women with breast cancer and with insomnia symptoms or using hypnotic medications participated to this three-arm randomized controlled trial: (1) PCBT-I (n = 81); (2) VCBT-I (n = 80); or (3) no treatment (CTL; n = 81) group. PCBT-I was composed of six weekly, individual sessions of approximately 50 min, whereas VCBT-I comprised a 60-min animated video and six booklets. RESULTS: Study measures (sleep and secondary variables) were administered at pretreatment and posttreatment, and at a 3-, 6-, and 12-mo follow-up. Treatment gains were well sustained at follow-up in both PCBT-I and VCBT-I. As at posttreatment, the remission rate of insomnia at follow-up was greater in PCBT-I than in VCBT-I, which was greater than in CTL. CONCLUSIONS: Although face-to-face therapy remains the optimal format to efficaciously administer CBT for insomnia in cancer patients, a minimal intervention, such as the video-based intervention tested in this study, produces significant and sustainable treatment effects. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00674830.

A randomized-controlled trial of an early minimal cognitive-behavioural therapy for insomnia comorbid with cancer.

OBJECTIVE: This study aimed to provide preliminary evidence on the efficacy of an early minimal cognitive-behavioural therapy for acute insomnia (mCBT-I) comorbid with cancer. METHOD: Thirty-eight patients (92% female; Mage 57; all Caucasian) with various types of cancer and having insomnia symptoms for less than 6 months were randomized to a self-administered mCBT-I condition (n=20; 6 short booklets + 3 phone consultations with a psychologist, over 6 weeks) or a no-treatment condition (n=18). Measures were completed at pre-treatment and post-treatment, as well as at 3- and 6-month follow-ups. RESULTS: All sleep parameters and the average dosage of hypnotics were significantly improved from pre- to post-treatment among treated participants, but not in control participants. mCBT-I was also associated with a significantly greater reduction of anxiety and depression symptoms, maladaptive sleep habits, and erroneous beliefs about sleep, as well as with a significantly greater improvement of subjective cognitive functioning. A greater proportion of mCBT-I participants than controls met the criteria for a clinical remission at post-treatment. Therapeutic gains of mCBT-I were well sustained up to 6 months after the intervention. CONCLUSIONS: This study supports the efficacy of an early minimal CBT-I to treat acute insomnia comorbid with cancer.

Cancer treatments and their side effects are associated with aggravation of insomnia: Results of a longitudinal study.

BACKGROUND: Insomnia affects between 30% to 60% of patients with cancer but to the authors' knowledge little is known regarding factors associated with its development. It has been postulated that adjuvant cancer treatments and their side effects could trigger sleep disturbances in this population but empirical evidence is lacking. The goal of the current study was to assess, separately in patients with breast and prostate cancer, the effect of adjuvant treatments on the evolution of insomnia symptoms and the mediating role of somatic symptoms. METHODS: As part of a population-based epidemiological study, patients with breast cancer (465 patients) and prostate cancer (263 patients) completed at baseline (perioperative period) and 2 months, 6 months, 10 months, 14 months, and 18 months later the Insomnia Severity Index (ISI) and a questionnaire assessing various somatic symptoms. RESULTS: In patients with breast cancer, radiotherapy (overall effect) and chemotherapy (at 2 months), but not hormone therapy, were associated with increased insomnia severity, whereas androgen deprivation therapy was related to increased insomnia in patients with prostate cancer. In patients with breast cancer, the effect of chemotherapy and radiotherapy on insomnia was found to be significantly mediated by a variety of somatic symptoms, whereas night sweats had a particularly marked mediating role for hormone therapy, both in patients with breast and prostate cancer. CONCLUSIONS: The findings of the current study indicate that cancer treatments and their side effects contribute to the aggravation of insomnia symptoms. Side effects of cancer treatments should be monitored more closely and managed as effectively as possible to prevent the occurrence or aggravation of insomnia.

Is anxiety associated with hot flashes in women with breast cancer?

OBJECTIVE: Women with breast cancer are at higher risk for experiencing hot flashes (HFs), which is attributable, in large part, to systemic cancer treatments and their effects on estrogen levels. However, other factors, such as anxiety, could also play a role. This study aimed to assess the cross-sectional and temporal relationships between anxiety and HFs among women treated for breast cancer and to clarify the direction of these relationships. METHODS: Fifty-six women recently treated for breast cancer were assessed prospectively using a 14-day Hot Flashes and Anxiety Diary (HFAD). Anxiety and HFs were also assessed using the Hospital Anxiety and Depression Scale-anxiety subscale and the Menopause-Specific Quality of Life Questionnaire-vasomotor subscale. In addition, HFs were objectively recorded for a continuous 24-hour period using home-based sternal skin conductance. RESULTS: No cross-sectional relationship was found between anxiety and subjectively assessed HFs, or between anxiety and the frequency and intensity of objectively assessed HFs. However, a greater anxiety level on the HFAD was significantly associated with a shorter time to reach the HF peak, as assessed with sternal skin conductance (partial Spearman correlation coefficient rsp = -0.44). Moreover, greater anxiety predicted more severe self-reported HFs on the following night, both assessed with the HFAD (rsp = 0.13). Conversely, self-reported diurnal and nocturnal HFs on the HFAD did not predict next-day anxiety level. CONCLUSIONS: This study reveals a significant relationship between anxiety and faster-developing objectively measured HFs. Furthermore, anxiety has been found to significantly predict subsequent increases in self-reported HFs, suggesting that strategies that target anxiety could potentially have a beneficial effect on HFs in women with breast cancer.

Is a video-based cognitive behavioral therapy for insomnia as efficacious as a professionally administered treatment in breast cancer? Results of a randomized controlled trial.

STUDY OBJECTIVE: To assess the short-term efficacy of a video-based cognitive behavioral therapy for insomnia (CBT-I) as compared to a professionally administered CBT-I and to a no-treatment group. DESIGN: Randomized controlled trial. SETTING: Radio-oncology department of a public hospital affiliated with Université Laval (CHU de Québec). PARTICIPANTS: Two hundred forty-two women with breast cancer who had received radiation therapy in the past 18 mo and who had insomnia symptoms or were using hypnotic medications were randomized to: (1) professionally administered CBT-I (PCBT-I; n = 81); (2) video-based CBT-I (VCBT-I; n = 80); and (3) no treatment (CTL; n = 81). INTERVENTIONS: PCBT-I composed of six weekly, individual sessions of approximately 50 min; VCBT-I composed of a 60-min animated video + six booklets. MEASUREMENT AND RESULTS: Insomnia Severity Index (ISI) total score and sleep parameters derived from a daily sleep diary and actigraphy, collected at pretreatment and posttreatment. PCBT-I and VCBT-I were associated with significantly greater sleep improvements, assessed subjectively, as compared to CTL. However, relative to VCBT-I, PCBT-I was associated with significantly greater improvements of insomnia severity, early morning awakenings, depression, fatigue, and dysfunctional beliefs about sleep. The remission rates of insomnia (ISI < 8) were significantly greater in PCBT-I as compared to VCBT-I (71.3% versus 44.3%, P < 0.005). CONCLUSIONS: A self-administered cognitive behavioral therapy for insomnia (CBT-I) using a video format appears to be a valuable treatment option, but face-to-face sessions remain the optimal format for administering CBT-I efficaciously in patients with breast cancer. Self-help interventions for insomnia may constitute an appropriate entry level as part of a stepped care model. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00674830. CITATION: Savard J, Ivers H, Savard MH, Morin CM. Is a video-based cognitive behavioral therapy for insomnia as efficacious as a professionally administered treatment in breast cancer? Results of a randomized controlled trial.

Validation of a sternal skin conductance criterion for measuring hot flashes in breast cancer patients.

OBJECTIVE: This study aimed to establish the sternal skin conductance level (SCL) increase that would optimally detect hot flashes among breast cancer patients. METHODS: Fifty-six women who had completed a similar treatment protocol for a first diagnosis of breast cancer within the previous 3 months wore an ambulatory sternal skin conductance device for one home-based daytime recording of hot flashes. RESULTS: A total of 199 hot flashes were reported by the participants using the event marker. A 2-µS (µmho) SCL increase within a 30-second period, the criterion typically used, had a sensitivity of only 32% and a specificity of 97%. Comparatively, the alternative criterion proposed here, a 1.2-µmho SCL increase, yielded a sensitivity of 61% and a specificity of 90%. CONCLUSIONS: This study provides evidence that a lower SCL criterion should be used to better detect objectively recorded hot flashes among breast cancer patients. Further work is needed to validate the proposed criterion among this population.

Relationship between objectively recorded hot flashes and sleep disturbances among breast cancer patients: investigating hot flash characteristics other than frequency.

OBJECTIVE: The aim of this study was to evaluate the relationship between various characteristics of objectively recorded hot flashes and sleep disturbances in breast cancer patients. METHODS: Fifty-six women who had completed a similar treatment protocol for a first diagnosis of breast cancer within the previous 3 months wore ambulatory sternal skin conductance and polysomnography devices for a home-based nighttime recording of hot flashes and sleep. RESULTS: Hot flash frequency was not associated with polysomnographic variables (r = -0.18 to 0.21) or beta-I and beta-II electroencephalographic activities (r = -0.01 and 0.03) but was significantly correlated with increased slow (r = 0.28) and delta (r = 0.32) electroencephalographic activities. A slower hot flash onset and a longer hot flash duration were associated with greater polysomnographic impairments (r = -0.50 to 0.48). Greater sleep disturbances were found during hot flash onset or hot flash plateau as compared with the pre-hot flash period (greater percentage of wake time, lower percentage of stage II sleep, and lower percentage of rapid eye movement sleep, all P values < 0.05). The probability that a stage change to a lighter sleep occurred was significantly greater during hot flash onset (11%) than during hot flash plateau (6%; P = 0.02). CONCLUSIONS: This study suggests that the speed and duration of hot flashes would contribute more importantly to sleep alterations than hot flash frequency. Sleep disturbances tend to occur simultaneously with hot flashes, suggesting that these two nocturnal symptoms are manifestations of a higher-order mechanism involving the central nervous system.